AI-enabled drug discovery continues to be a hot topic in 2024. “It is really starting to reshape the biotech industry” said Renana Ashkenazi, General Partner at Grove Ventures, to TechCrunch’s newsletter, the Exchange.
“Innovation and progress towards a detailed model of human cells, combined with the fact that big pharma’s returns on R&D are not as good as they used to be, create a unique market opportunity. In the near future, we will see more big pharma companies increasing AI-driven drug discovery and development activities,” she predicted.
>> Click here to read the full item originally published on TechCrunch:
